The eleventh batch of national organized drug centralized procurement opened bidding. The selected products meet the diverse needs of clinical and patients.

On October 27, 2025, the results of the 11th batch of national centralized procurement of drugs were announced. A total of 55 drugs were included in this procurement, covering commonly used drugs in the fields of anti-infection, anti-allergy, anti-tumor, lowering blood sugar, lowering blood pressure, lowering blood lipid, anti-inflammatory and analgesic. A total of 46,000 medical institutions nationwide participated in the bidding, with 794 products from 445 enterprises participating in the bidding, of which 453 products from 272 enterprises were selected as potential winners. This procurement was implemented in accordance with the decision deployment made at the State Council executive meeting to promote the normalization, institutionalization, and regularized development of centralized procurement work, achieving the expected goals of "stabilizing clinical treatment, ensuring quality, preventing vicious competition, and preventing bidding manipulation". Firstly, the selected products are more matched with the needs of medical institutions, strengthening the stability in clinical treatment. Medical institutions can request procurement based on either generic names or brand names, and 75% of the procurement requests were met according to the selection results, indicating a high degree of matching between the selected brands and clinical needs. Mainstream enterprises with strong supply capabilities and guaranteed quality were mostly selected, and each region has multiple selected enterprises supplying goods, making the variety of selected products more diverse. Secondly, the qualification threshold for bidding enterprises has been raised to improve quality assurance. Bidding enterprises are required to have experience in producing similar drugs and must ensure that there have been no violations of drug production quality standards in the production line of the bidding drug in the past 2 years. The drug regulatory authorities will conduct comprehensive supervision and inspections on the selected products. Thirdly, guiding enterprises to quote rationally, clearly opposing vicious competition. The competition in this procurement was more intense than in the previous ten batches. Measures were taken to prevent extreme low-price competition, such as not including products under 100 million yuan, setting an "anchor price" to prevent extreme low-price impact, introducing a revival mechanism, and guiding enterprises to quote scientifically through repeated promotion. This has maintained a high rate of selection, and the average price difference of selected products has significantly decreased compared to previous batches. Lastly, the bidding behavior throughout the entire chain was standardized to prevent bidding manipulation. Enterprises with equity relations, production outsourcing, or license transfer relationships were deemed as one entity to prevent colluding in bidding. The introduction of a lenient "first report" mechanism aimed at breaking up the interest alliances among bidders. The implementation of the drug price and procurement credit evaluation system strengthened the deterrence against bid manipulation. This guided the industry to collectively maintain a fair competitive market order. Up to now, the State Medical Insurance Bureau has carried out eleven batches of national centralized drug procurement, successfully procuring 490 drugs. The selected results of this procurement will be officially announced after the public notice, and it is expected that patients across the country will have access to a new batch of quality-assured and cost-effective selected drugs in February 2026. This article is from "Cai Lianshe". Editor: Xu Wenqiang.